<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644237</url>
  </required_header>
  <id_info>
    <org_study_id>DS8201-A-U206</org_study_id>
    <nct_id>NCT04644237</nct_id>
  </id_info>
  <brief_title>Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>DESTINY-LUNG02</acronym>
  <official_title>A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in&#xD;
      HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease&#xD;
      recurrence or progression during/after at least one regimen of prior anticancer therapy&#xD;
      (second line or later) that must have contained a platinum-based chemotherapy drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, two-arm, phase 2, multicenter study will evaluate the safety and efficacy of&#xD;
      5.4 mg/kg and 6.4 mg/kg trastuzumab deruxtecan administered every 3 weeks (Q3W) in&#xD;
      participants with HER2-mutated metastatic NSCLC. Each participant is expected to receive&#xD;
      approximately 14 months of trastuzumab deruxtecan treatment. The primary endpoint of the&#xD;
      study will be objective response rate (independent central review). Secondary endpoints will&#xD;
      include, but not limited to, disease control rate, duration of response, progression-free&#xD;
      survival, objective response rate (investigator), overall survival, and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors</measure>
    <time_frame>9 months after the last participant is randomized or later, up to approximately 31 months</time_frame>
    <description>Confirmed objective response rate (ORR), defined as the proportion of participants with complete response (CR) or partial response (PR), will be assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors</measure>
    <time_frame>9 months after the last participant is randomized or later, up to approximately 31 months</time_frame>
    <description>Confirmed objective response rate (ORR), defined as the proportion of participants with complete response (CR) or partial response (PR), will be assessed by the Investigator based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer</measure>
    <time_frame>9 months after the last participant is randomized or later, up to approximately 31 months</time_frame>
    <description>Duration of response (DoR) is defined as the time from the initial response (complete response [CR] or partial response [PR]) until documented tumor progression or death from any cause. DoR is only defined for participants who achieved confirmed CR or PR. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer</measure>
    <time_frame>9 months after the last participant is randomized or later, up to approximately 31 months</time_frame>
    <description>Disease control rate (DCR) is the sum of complete response (CR), partial response (PR), and stable disease (SD) rates. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer</measure>
    <time_frame>9 months after the last participant is randomized or later, up to approximately 31 months</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from date of randomization until first objective radiographic tumor progression or death from any cause, based on blinded independent central review (BICR) and investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors</measure>
    <time_frame>9 months after the last participant is randomized or later, up to approximately 31 months</time_frame>
    <description>Overall survival (OS) is defined as the time from date of randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors</measure>
    <time_frame>Baseline up to 40 days after last dose, up to approximately 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a</measure>
    <time_frame>Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter Minimum Observed Concentration (Ctrough) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a</measure>
    <time_frame>Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter Area Under the Serum Concentration-Time Curve (AUC) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a</measure>
    <time_frame>Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-Drug Antibodies (ADA) Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2 and 4, and then every 4 cycles (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores</measure>
    <time_frame>On Day 1 of every cycle (each cycle is 21 days), and at end of treatment visit 40-day follow-up visit</time_frame>
    <description>The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms. The QLQ-LC13 is a 13-item questionnaire designed to assess lung cancer-related symptoms and treatment side effects. The scales ranges from 1=not at all to 4=very much. The summation of scores range from 0 to 100, where higher scores represent increasing symptoms levels.&#xD;
scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) scores</measure>
    <time_frame>On Day 1 of every cycle (each cycle is 21 days), and at end of treatment visit 40-day follow-up visit</time_frame>
    <description>The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab deruxtecan 6.4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive trastuzumab deruxtecan 6.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab deruxtecan 5.4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive trastuzumab deruxtecan 5.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab deruxtecan</intervention_name>
    <description>Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL [ie, 100 mg/5 mL]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.</description>
    <arm_group_label>Trastuzumab deruxtecan 5.4 mg/kg</arm_group_label>
    <arm_group_label>Trastuzumab deruxtecan 6.4 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Men or women ≥18 years, follow local regulatory requirements if the legal age of the&#xD;
             consent for study participation is &gt;18 years&#xD;
&#xD;
          -  Pathologically documented metastatic NSCLC with a known activating HER2 mutation.&#xD;
             Note: A HER2 mutation documented only from a liquid biopsy samples cannot be used for&#xD;
             enrollment.&#xD;
&#xD;
          -  Had previous treatment (second line or later [2L+], including platinum therapy), not&#xD;
             amenable to curative surgery or radiation&#xD;
&#xD;
          -  Presence of at least 1 measurable lesion confirmed by the blinded Independent Central&#xD;
             Review based on RECIST version 1.1&#xD;
&#xD;
          -  Willing and able to provide an archival tumor tissue sample. A fresh biopsy is&#xD;
             required if an archival tumor tissue sample cannot be supplied. Fine needle aspirates&#xD;
             are not acceptable.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0 to 1&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ 50% within 28 days before randomization&#xD;
&#xD;
          -  Adequate organ function as specified in protocol within 14 days before randomization&#xD;
&#xD;
          -  Adequate treatment washout period before randomization&#xD;
&#xD;
          -  Participants of reproductive/childbearing potential agree to use a highly effective&#xD;
             form of contraception (or avoid intercourse) during study period and up to 7 months&#xD;
             (females) and 4 months (males) after last study dose&#xD;
&#xD;
          -  Males should not freeze or donate sperm throughout the study period up to at least 4&#xD;
             months after last study dose; females should not donate or retrieve ova for their own&#xD;
             use throughout the study period and up to at least 7 months after last study dose&#xD;
&#xD;
          -  Life expectancy 3 months or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known driver mutation in the epidermal growth factor receptor (EGFR) or BRAF gene or a&#xD;
             known anaplastic lymphoma kinase (ALK) or ROS1 fusion&#xD;
&#xD;
          -  Medical history of myocardial infarction within 6 months before randomization,&#xD;
             symptomatic congestive heart failure (CHF) (New York Heart Association Class II to&#xD;
             IV). Participants with troponin levels above upper limit of normal at screening (as&#xD;
             defined by the manufacturer) and without any myocardial infarction (MI)-related&#xD;
             symptoms should have a cardiologic consultation before enrollment to rule out MI&#xD;
&#xD;
          -  Corrected QT interval (QTcF) prolongation &gt; 470 msec (females) or &gt;450 msec (males)&#xD;
             based on average of the triplicate12-lead electrocardiogram at screening&#xD;
&#xD;
          -  History of non-infectious interstitial lung disease (ILD)/pneumonitis that required&#xD;
             steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled&#xD;
             out by imaging at screening&#xD;
&#xD;
          -  Spinal cord compression or clinically active central nervous system metastases,&#xD;
             defined as untreated and symptomatic, or requiring therapy with corticosteroids or&#xD;
             anticonvulsants to control associated symptoms&#xD;
&#xD;
          -  Multiple primary malignancies within 3 years, except adequately resected non-melanoma&#xD;
             skin cancer, curatively treated in-situ disease, or other solid tumors curatively&#xD;
             treated&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to either the drug substances or inactive&#xD;
             ingredients in the drug product&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to other monoclonal antibodies&#xD;
&#xD;
          -  Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals&#xD;
&#xD;
          -  Substance abuse or any other medical conditions such as clinically significant cardiac&#xD;
             or psychological conditions, that may, in the opinion of the investigator, interfere&#xD;
             with the participant's participation in the clinical study or evaluation of the&#xD;
             clinical study results&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Known active, clinically relevant liver disease (eg, active hepatitis B, or active&#xD;
             hepatitis C), based on available blood tests, liver ultrasound, or liver biopsy&#xD;
             results&#xD;
&#xD;
          -  Unresolved toxicities from previous anticancer therapy, defined as toxicities (other&#xD;
             than alopecia) not yet resolved to Grade ≤ 1 or baseline&#xD;
&#xD;
          -  Pregnant, breastfeeding, or planning to become pregnant&#xD;
&#xD;
          -  Otherwise considered inappropriate for the study by the Investigator&#xD;
&#xD;
          -  Lung-specific intercurrent clinically significant illnesses including, but not limited&#xD;
             to, any underlying pulmonary disorder (eg. pulmonary emboli within three months of the&#xD;
             study randomization, severe asthma, severe COPD, restrictive lung disease, pleural&#xD;
             effusion, etc.)&#xD;
&#xD;
          -  Any autoimmune, connective tissue or inflammatory disorders (e.g., Rheumatoid&#xD;
             arthritis, Sjogren's, sarcoidosis etc.) where there is documented, or a suspicion of&#xD;
             pulmonary involvement at the time of screening&#xD;
&#xD;
          -  Prior complete pneumonectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>(US sites) Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>908-992-6400</phone>
    <email>CTRinfo@dsi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>(Japan Sites) Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>+81-3-6225-1111(M-F 9-5 JST)</phone>
    <email>dsclinicaltrial@daiichisankyo.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver - Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute/Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virgina Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St John of God Subiaco Hospital</name>
      <address>
        <city>Subiaco</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Townsville University Hospital</name>
      <address>
        <city>Townsville</city>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <zip>M5G0A3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille AP-HM, Hopital NORD</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU toulouse - hÃ´pital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustav Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luca</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SC Oncologia, AOU Policlinico Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Strutturadi Oncologia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Cancer Center Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Chikusa</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Central Hospital</name>
      <address>
        <city>Chuo Ku</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>11111</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <zip>277-0882</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Ōsaka-sayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>6351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System - Severance Hospital</name>
      <address>
        <city>Sinchon-dong</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i PolitÃ¨cnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital NCKUH</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital CGMH - LinKou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Trastuzumab Deruxtecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

